A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Status:
Recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a
combination-specific module) study of DCC-3116 in combination with anticancer therapies.
Modules within the master protocol are defined according to different combinations of
DCC-3116 with other anticancer agents.